Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000301
Chunk: 97

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 97
---
 Company
or any Subsidiary of the Company shall default beyond applicable grace and cure periods in any of its obligations under any other debenture
or any, mortgage, credit agreement or other facility, indenture agreement, factoring agreement or other instrument under which there may
be issued, or by which there may be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing
or factoring arrangement of the Company or any Subsidiary of the Company in an amount exceeding $100,000, whether such indebtedness now
exists or shall hereafter be created and such default shall result in such indebtedness becoming or being declared due and payable;

(iv) The ADSs shall
cease to be quoted or listed for trading, as applicable, on any Primary Market as a result of failure to comply with the listing standards
thereof or a voluntary delisting for a period of five (5) consecutive Trading Days;

(v) The Company’s
failure to timely file with the Commission any Periodic Report on or before the due date of such filing as established by the Commission,
it being understood, for the avoidance of doubt, that due date includes any permitted filing deadline extension under the Exchange Act;

(vi) Any representation
or warranty made by the Company on Annex A hereto or made or deemed to be made by the Company in or in connection with any Transaction
Document, or any waiver hereunder or thereunder, shall prove to have been incorrect in any material respect (or, in the case of any such
representation or warranty already qualified by materiality, such representation or warranty shall prove to have been incorrect) when
made or deemed made;

(vii) Any material
provision of any Transaction Document, at any time after its execution and delivery and for any reason other than as expressly permitted
hereunder or thereunder, ceases to be in full force and effect; or the Company or any other Person contests in writing the validity or
enforceability of any provision of any Transaction Document; or the Company denies in writing that it has any or further liability or
obligation under any Transaction Document, or purports in writing to revoke, terminate (other than in line with the relevant termination
provisions) or rescind any Transaction Document;

(viii) the Company
uses the proceeds of the issuance of this Note, whether directly or indirectly, and whether immediately, incidentally or ultimately, to
purchase or carry margin stock (within the meaning of Regulations T,